Background: Two-stage revision is regarded by many as the best treatment of chronic infection in hip arthroplasties. Some international reports, however, have advocated one-stage revision. No systematic review or meta-analysis has ever compared the risk of reinfection following one-stage and two-stage revisions for chronic infection in hip arthroplasties.
Introduction
Much has been written in past decades on the treatment of infected hip arthroplasties (HA), as infection constitutes a major cause of revision. 1 The incidence of deep infection following HA has stabilized at less than 1%. [2] [3] [4] [5] This severe complication to an otherwise very successful procedure is a large personal and economic burden to the patient and very costly from a societal perspective. 4, 6, 7 Current treatment options involve a panel of surgical and nonsurgical approaches. 8 Antibiotic suppression therapy is used if the patient is very ill or declines further surgical treatment. 8, 9 Debridement and antibiotic treatment combined with implant retention is used in early and acute hematogenous infections, but is inferior in chronic infections. [10] [11] [12] Direct exchange (one-stage revision) or delayed reimplantations (primarily as two-stage revision) are used in chronic infections. Two-stage revision is currently regarded as the surgical gold standard worldwide. 8, 9, [13] [14] [15] [16] The one-stage approach, pioneered by Buchholz three decades ago, is advocated mainly by European centers. 15, 17 One-stage revision has the presumed advantages of a lower personal burden for the patient, a societal economic gain, and an overall better outcome due to fewer surgical procedures and lack of an interim period. The last large review on one-stage revision in the treatment of infected HA was published a decade ago. 18 The authors concluded on the basis of 1299 episodes of infected HA treated by one-stage revision that the indication for one-stage revision was limited due to a high reinfection risk (17% reinfected). The risk estimate was obtained by pooling cases from twelve studies. Cases represented a mixture of acute and chronic infections, and no evaluation of the quality of the research data was performed. Furthermore, no direct comparison was made with other treatment strategies. We found it appropriate to investigate systematically the current evidence for best practice in the treatment of chronic infections in HA, with a focus on retention of a functional hip implant. We performed, to our knowledge, the first systematic review and meta-analysis comparing the risk of reinfection following one-stage and two-stage revision for chronic infection in HA.
Materials and methods
The study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. 19, 20 Our aim was to examine whether onestage revision is a relevant treatment strategy for chronic infection in HA with respect to the primary-outcome reinfection, as compared to the currently accepted gold standard of two-stage revision. All types of study designs were accepted for inclusion in this review.
Search strategy
Studies were identified by electronic-database searching of PubMed (1966 ( -May 2010 , Embase (1980 -May 2010 , the Cochrane Library, and the World Health Organization platform for international clinical trials registries (http://www. who.int/ictrp). We used a search strategy developed by the first author and a university research librarian, as specified in Table 1 . 21 Reference lists of all acquired original and review articles were assessed for relevance and cross-referenced with articles already obtained ("snowballing"). Studies were subjectively assessed by title in the electronic-database search (see criteria used in Table 1 ), and if deemed relevant, the abstract was retrieved. In cases of possible relevance based on the abstract, the full-length text was obtained. In cases where no abstract was available, the full-length text was obtained.
Eligibility criteria
From the full-length texts obtained, we included all studies that examined patients with an HA and a diagnosed infection of the implant, for whom a defined duration of symptoms or time period from the index implantation to the infection diagnosis was given, who were treated with either one-stage or two-stage revision, and for whom data on occurrence and number of reinfections were available. Selected relevant patient subgroups from broader studies were also able to be included. No restrictions were made according to age, gender, presence of comorbidity, infecting microorganism, primary hip disease, and nature of the index implant or length of patient follow-up. We did not include patients who had received treatment for a new infection following a prior septic revision, regardless of time interval, or patients who did not complete a reimplantation as part of a planned twostage revision but were discharged following a Girdlestone/ permanent-spacer procedure. We chose to compare only patients with completed one-stage and completed twostage revision, as we considered this the clinically relevant treatment exposure of interest. Only patients reported in full-length articles were included for analysis. Studies with overlapping patient data were individually assessed and the most appropriate study chosen for inclusion (based on available information and longest follow-up). Eligibility assessment was done by the first author.
Data processing
The following variables were registered: (1) main exposure -patients undergoing one-stage/two-stage revision with completed reimplantation; (2) primary outcomereinfection; (3) study demographics -first author, publication year, the institution where patients were operated on, the calendar period of inclusion, presence of a study hypothesis, a predefined primary end point, clearly defined in-and exclusion criteria, study design, retrospective or prospective data collection; (4) study population demographics -definition of infection, defined time period between latest surgery to the hip and subsequent infection, duration of infection symptoms prior to revision, the total number of patients eligible for reimplantation,
Studies identified through database searching
Medline (n = 336) Embase (n = 426)
Additional included studies:
Identified through bibliographic cross-reference of obtained articles and existing reviews, based on relevancy by title and further screening of abstract (n = 40)
Relevancy based on title with abstract screened (full text if abstract non-available) Medline + Embase (n = 180)
Original articles obtained (n = 125) 
Summary measures
We performed meta-analysis estimating the absolute risk (hereafter referred to simply as "risk") with 95% confidence intervals of the primary outcome with a random-effects model. The analysis was performed using extracted patient data from the individual studies. Subgroup analysis on the risk of reinfection was done for main exposure and further stratified by type of implant used at reimplantation. We performed meta-regression for all studies and stratified by main exposure regarding study size and publication year on risk of reinfection. We performed sensitivity analysis by means of "one-study removed" to detect outliers and evaluate single-study impact on the derived estimates. By a priori acknowledgment of significant inconsistency among studies and by taking this into account using a random-effects model, we did not further quantify existing heterogeneity. 22 All data management was done using Comprehensive Meta-Analysis (v2.0; BioStat, Englewood, NJ). In the case of zero-outcome events, this program adds 0.5 to the value of both outcome events and sample size and uses these modified values for all future calculations (eg, no events in 20 patients: 0.5/20.5 = risk of 0.024). Forest plots were produced to qualitatively evaluate study heterogeneity and graphically support risk estimates. Funnel plots were used to graphically assess the possibility of publication bias. Such bias was believed a priori to exist for small studies with poor results. 23 Assessment of methodological or clinical limitations for the included studies was done with a focus on key study features, these being: (1) patient sample -well-defined inclusion criteria, mode of data collection, defined patient demographics; (2) follow-upsufficiently defined as more than 2 years; (3) outcome -adequate description regarding infection diagnosis; and (4) treatmentperioperative treatment regimens.
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Results
Study selection
A total of 165 full-length articles were assessed for eligibility ( Figure 1 ). Of these, 36 studies were considered eligible for 
Description of included studies
Study characteristics are summarized in Tables 2 and 3 . The patients in the 36 included studies were divided into two cohorts of distinctly separate revision strategies: a onestage-revision cohort (Table 2 ) comprising relevant patients from ten studies (n = 375 [cementless reimplantation, n = 25 patients; [47] [48] [49] cemented reimplantation, n = 350 patients [49] [50] [51] [52] [53] [54] [55] ) and a two-stage-revision cohort (Table 3 ) comprising relevant patients from 28 studies (n = 929 [cementless reimplantation, n = 189 patients; 48, [56] [57] [58] [59] [60] [61] [62] cemented reimplantation, n = 177 patients; [63] [64] [65] [66] [67] [68] [69] no specific information on type of reimplantation at patient level, n = 563 patients 11, 13, 16, [70] [71] [72] [73] [74] [75] [76] [77] [78] ]). Gender and age did not differ between the cohorts based on the available data. In the one-stage cohort, 195 of 365 (53.4%) patients were male, compared to 400 of 699 (57.2%) patients in the two-stage cohort, although 230 of 929 (24.8%) patients in the two-stage cohort had no data on gender, compared to ten of 375 patients in the one-stage cohort. The reported average age in the one-stage cohort was 61.4 years, compared to 63.1 years in the two-stage cohort. Data on comorbidity on a patient level or for the study cohort as a whole were only available in 14 studies (in only one of ten studies with patients in the one-stage cohort, compared to 14 of 28 studies with patients in the two-stage cohort). Thirteen of the 36 studies originated from North America, eleven from Europe, nine from Asia/Australia and three from South America. In the one-stage cohort, 280 of 375 (75.0%) patients originated from European studies, as did 261 of 929 (28.1%) in the two-stage cohort. In contrast, only 44 of 375 (11.7%) patients in the one-stage cohort and 445 of 929 (48.0%) patients in the two-stage cohort originated from North American studies. The one-stage cohort studies tended to be older: six of ten studies were published in the period 1990-1999 and three of ten studies were published after 1999, whereas in the two-stage cohort seven of 28 studies were published in the period 1990-1999 and 20 of 28 studies after 1999. Regarding the methodology of the included studies, we found no comparative studies that compared patients exposed to one-stage revision with a concurrent or historical control group of patients with two-stage n/a n/a n/a (6-24weeks) revision, or vice versa. One study was a randomized trial of spacer versus no-spacer treatment in patients who had all had two-stage revision. 16 Another study was a casecontrol study in patients with performed two-stage revision had become infected with resistant versus nonresistant microorganisms. 73 One study used cohort-outcome analysis to examine predictors of reinfection. 63 The remaining 33 of the 36 (92%) studies were purely descriptive case series of infected HA patients treated with one-stage or two-stage revision, reporting patient characteristics and frequencies of different outcomes, including reinfection. Twenty-eight of 36 (78%) studies used retrospective data collection. Only two studies described a priori defined primary end points. Three studies stated a study hypothesis, and 14 studies provided some degree of background information on inand exclusion criteria for enrollment in the study. Eighteen studies did not report on the status of the infected index HA (being a primary/revision or cemented/cementless prosthesis). Fifteen studies evaluated the revision procedure by means of the Harris hip score. 11, 16, 47, 48, 50, [57] [58] [59] 61, 64, [68] [69] [70] 77, 79 Twelve studies did not use a standardized scoring system in evaluating patients postoperatively. 13, 51, 52, 55, 60, 63, 65, 66, [71] [72] [73] 80 Four studies used the Merle d'Aubigné-Postel score. 49, 54, 56, 75 The remaining five studies used other scoring systems. 53, 62, 67, 74, 78 Methodological characteristics of the included studies are shown in Table 4 . In conclusion, methodological quality was considered low for most included studies, and we found no comparative studies examining one-stage versus two-stage revision.
Meta-analysis
We pooled data from 36 studies with a total of 1304 patients having a completed one-stage or two-stage revision and 126 registered reinfections following the reimplantation. Sensitivity analysis did not detect outliers, nor did it indicate that any estimate was heavily determined by a particular study. We found that reinfections for all studies occurred with an estimated risk of 11.3% (95% confidence interval [CI]: 9.6%-13.2%) (Figure 2 (Figure 3 ). In the two-stage cohort, cementless reimplantation yielded a reinfection risk of 8.6% (95% CI: 4.9%-14.7%), and cemented reimplantation a reinfection risk of 12.3% (95% CI: 8.0%-18.4%) (Figure 4 ). In the one-stage cohort, only very limited data were available for cementless reimplantation (a total of just 25 cases). Meta-regression showed no correlation between study size and risk of reinfection pooling all studies (β = 0.002, P = 0.172) or within the two-stage cohort (β = -0.002, P = 0.486). However, within the one-stage cohort, a larger study size correlated with a higher risk of reinfection (β = 0.005, P = 0.048). Further exploration showed that the single study by Raut et al 54 had a considerable role in this correlation, with a relative weight of 62% in the onestage group; however, this was not detected as statistically significant by sensitivity analysis. Meta-regression indicated that a more recent publication pooling all studies correlated with a lower risk of reinfection (β = -0.029, P = 0.020), but no correlation could be identified when stratified (one-stage cohort: β = -0.032, P = 0.346; two-stage cohort: β = -0.026, P = 0.098). Graphical evaluation of funnel plots confirmed the likely presence of missing smaller studies with higher reinfection risk.
Discussion
Summary of evidence
The results of this meta-analysis suggest the presence of nearly three additional reinfections per 100 reimplanted patients when performing a one-stage revision compared to a two-stage revision strategy for treatment of chronic infection in HA. However, we believe it is difficult to draw any conclusions on the superiority of either revision strategy from the available data. Even with the reasonably large number of studies, the pooled reinfection-risk estimates were statistically imprecise, with overlapping confidence intervals. Furthermore, one must consider that these risk estimates are based purely on data from case series with limited information on potential confounding factors. No single study has directly compared the two revision strategies. Also, the different submit your manuscript | www.dovepress.com clinical settings and patients underlying the two revision strategies must be taken into account. Nevertheless, we have demonstrated the lack of clear evidence proving one-stage revision to be a less effective treatment strategy for chronic infections in HA, as has been previously claimed. 18 
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Strengths and limitations
The data presented in this review are the best available at present to clinicians worldwide, and have so far been used to advocate the different treatment strategies offered. 9, 18 We quantified these data for the first time in a systematic review and meta-analysis. Yet it became apparent that neither controlled clinical trials nor observational studies have directly compared one-stage and two-stage revision for treatment of chronic infections in HA. The estimates obtained in this review are obtained from a wide diversity of patients, the majority of studies were small and based on retrospective data collection, and results from the two cohorts should be compared with great caution. Due to the unavailability of confounding factors in many of the studies, we chose simply to estimate pooled absolute risks of reinfection in the two cohorts, rather than a risk-ratio estimate in a direct comparison, as we had no way to control for potentially skewed distribution of covariates. Ignoring this would in our opinion compromise the entire study. We thus believe the reported absolute estimate gives a fair opportunity for better understanding the conclusions drawn from this review. 81 Yet several aspects must be emphasized.
Terminology
Infection in HA is by far the most difficult area to define, as this is often covered by a multitude of overlapping symptoms and clinical findings, which added together strongly indicate a septic complication. Even the gold standard in diagnosing infection -perioperative cultures -is not absolute. Culturenegative patients may still be infected, and single-or even double-positive culture may represent contamination. 82, 83 Several different definitions of infection have been used in the included studies (Tables 2 and 3 ). We chose a pragmatic approach for our review, and defined the presence of infection as defined by the authors of the individual study. However, as the definition of infection and reinfection in the 36 included studies varied considerably, ranging from "infection"/ clinical features of infection to obtainment of positive bacterial cultures, the risk of misclassification is inherent. For example, patients with aseptic loosening may have been misclassified as reinfected, whereas patients with true infection who did not undergo reoperation after revision may have been missed. Many definitions of "chronic infection" exist. 8, 11, 13, 29, 45, [84] [85] [86] 87 A priori, we aimed to define chronic infections according to McPherson, as infections with a duration of symptoms above 4 weeks, regardless of origin. 88 This has also been advocated by others as the best definition at present and has been used recently, in studies of arthroplasty infections and HA studies in particular, by multiple international orthopaedic centers. 13, 26, 77, [89] [90] [91] However, during study selection, it became apparent that the definition by McPherson 88 was very difficult to apply to the existing literature, as many studies reported only the interval from last operation to subsequent revision or from last operation to diagnosis of infection. Subsequently, we also chose to include studies that defined chronic infections as more than 1 month since last surgery, regardless of symptom duration, and by authors stating an infection as chronic (Tables 2 and 3) . 11 If no data were available regarding these time limits, the study or patients were not included in our review. Thus we may have included patients with acute hematogenous infections, and we may have excluded potentially eligible patients from our analysis. A very strict definition of chronic infection at patient level is thus an element not taken into account in this analysis, as these data were not available to the authors.
Risk-factor assessment
Many apparent risk factors have been suggested to predict worse outcomes when treating infected hip arthroplasties, but few have been validated and the quality of evidence is poor. led to an overestimation of the reinfection risk associated with one-stage procedures conducted many years ago. As our understanding of the importance of many different treatment aspects increases over time, so may our overall results improve, regardless of the chosen surgical strategy. The articles from which data are analyzed span more than two decades; surgical techniques and materials used have evolved, as well as general knowledge on infections and patient care. Undoubtedly, better knowledge of optimal antibiotic therapy in prophylactic and active treatment, eg, the use of antibioticenriched cement and differences in local resistance patterns, but also the emergence of multiresistant organisms, could have influenced the reinfection risk over time. Improved understanding of biofilm-producing microorganisms is submit your manuscript | www.dovepress.com
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essential in today's aggressive debridement approach, recognizing the need for absolute removal of dead matter and foreign materials. Our review does not take these important developments over time into account, as good data on these risk factors do not exist in the present studies. Comorbidity, high American Society of Anesthesiologists score, long duration of the surgical procedure, and low hospital and surgeon volume have been suggested as important risk factors for reinfection. 5 In contrast, gender or increased age apparently do not constitute important risk factors, but data quality is poor and conflicting evidence exists. 5, 92 Age and gender were also quite evenly distributed in the onestage and two-stage cohorts in this review. Explicit data on comorbidity at a patient level or even just study level is absent from most studies, as only 14 of 36 studies reported this data. In our opinion, the apparent large difference in reported patient comorbidity (10% among one-stage studies versus 50% among two-stage studies) is most likely due to underreporting, not ignoring that a possible genuine lower comorbidity in the one-stage cohort on the other hand may have led to an underestimation of the reinfection risk associated with this procedure. Furthermore, certain types of medication may directly constitute risk factors, including treatment with bisphosphonates. 93 However, information on medical treatment of the included study populations is not available. The chosen antibiotic treatment strategy is an area of specific interest regarding reinfection, as the surgical procedure by itself does not resolve the infection. Furthermore, the nature of the infecting microorganism may be a key element regarding outcome. Thus, Gram-negative organisms, multiresistant organisms, and polymicrobial infections have been proposed to predict worse outcomes. As shown in Tables 3 and 4 , this information is not readily available in the existing studies to a degree at which we could adjust for any differences in these and other risk factors in our meta-analysis.
Potential bias
Whether to choose a specific surgical intervention in a non-research, everyday clinical practice environment is determined by many factors. This raises the concern of whether the selection of patients in the individual 36 studies is alike, with consequences for the comparability of the two cohorts in this review. As noted above, a potentially skewed distribution of unreported or unknown confounders may exist. Confounding by indication (surgical bias) could potentially influence the results obtained in this analysis, as surgeons may choose less severely ill patients (eg, with known nonresistant microorganisms) for one-stage revision. By the very nature of two-stage surgery, the surgeon is able to evaluate the progress before reimplantation, this being one of the clinical strengths of this approach compared with onestage revision. The exclusion in our meta-analysis of patients for whom the second stage was not completed may favor the two-stage approach, since the patients who did not undergo the second stage may constitute a group with poor outcomes. Finally, by limiting our search to English-and Germanlanguage studies from only two electronic databases, we may have overlooked studies published in nonindexed journals, or data presented at national or international conferences, which most likely would include more unfavorable results.
implications for future research
We believe that complications and outcomes (including validated patient-related outcomes measures) of the different revision strategies need more research attention. Recently, the proportion of complications with interim-spacer application has been reported as high as 60%, and fatal complications have also been reported. 16, 91 Appropriate patient selection seems to be a crucial aspect of success. 15, 40, 94 Given the complexity and relative scarcity of patients with chronically infected HA, randomized clinical trials may prove difficult to perform. The estimates obtained in our analysis suggest that a sample size of more than 3500 infected patients would be needed to investigate superiority of two-stage versus onestage revision regarding reinfection with statistical precision. Meanwhile, we recommend adoption of standardized reporting of essential data among patients treated for chronically infected HA to ensure the future possibility of performing improved collaborative meta-analysis. 21 We thus recommend that future publications on this matter include relevant individual patient information, making it possible to pool data on a patient level, including detailed data on potential risk factors, duration since last surgical procedure, the duration of symptoms, clear information regarding diagnosis of infection, and grade according to the modified McPherson staging system. 13 
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